Comparative Pharmacology
Head-to-head clinical analysis: CYCLOPENTOLATE HYDROCHLORIDE versus ISOPTO ATROPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOPENTOLATE HYDROCHLORIDE versus ISOPTO ATROPINE.
CYCLOPENTOLATE HYDROCHLORIDE vs ISOPTO ATROPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antimuscarinic agent; blocks acetylcholine at muscarinic receptors in the sphincter and ciliary muscles of the iris, producing mydriasis and cycloplegia.
Antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, resulting in mydriasis and cycloplegia.
1-2 drops of 0.5-1% solution, repeat in 5-10 minutes if necessary; or 0.1-0.5 mL of 1% solution subconjunctivally.
1 to 2 drops of 1% solution in the affected eye(s) up to four times daily for cycloplegic refraction; for uveitis, 1 to 2 drops up to three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours in adults; shorter in children (~1-2 hours) and prolonged in elderly or hepatic impairment.
2.5-3.0 hours (terminal elimination half-life in adults); may be prolonged in elderly and children due to reduced metabolic clearance
Renal excretion of unchanged drug and metabolites accounts for approximately 60-70% of elimination; the remainder is biliary/fecal.
Renal (70% as unchanged drug and metabolites within 24 hours); fecal (30%)
Category C
Category C
Ophthalmic Anticholinergic
Ophthalmic Anticholinergic